RECOMBINANT COAGULATION FACTOR VIIA

Recombinant human coagulation Factor VIIa (rFVIIa) is used to treat hemorrhagic problems caused by hemophilia A and B. It promotes hemostasis by triggering the pathway of the coagulation cascade.

Uses

For treatment of hemorrhagic complications in hemophilia A and B

Warnings

Do not give this drug to people with the following conditions:

Hypersensitivity to eptacog alfa (activated) or to mouse protein
Rare hereditary problems of fructose intolerance
Glucose malabsorption or sucrose-isomaltase insufficiency

Side Effects

Recombinant Coagulation Factor VIIA may have the following side effects:

Venous thromboembolic events
Pruritus
Pyrexia

Precautions

Precautions

Take extra caution in patients with the following medical conditions:

Advanced atherosclerotic disease
Crush injury
Septicaemia or disseminated intravascular coagulation
Patients with history of heart disease
Liver disease
Undergoing major surgery
Risk of thromboembolic phenomena or disseminated intravascular coagulation
Pregnancy
Lactation
Neonates

Interactions

Recombinant Coagulation Factor VIIA may interact with the following medicines:

Prothrombin complex concentrates (activated or not)
Antifibrinolytics; rFXIII

Overdose & Brands

If you think you have used more Recombinant Coagulation Factor VIIA than the usual dosage, please seek medical help immediately.

Available Brands:

Novo Seven